000165166 001__ 165166
000165166 005__ 20251219174251.0
000165166 0247_ $$2doi$$a10.18176/jiaci.0075
000165166 0248_ $$2sideral$$a106040
000165166 037__ $$aART-2016-106040
000165166 041__ $$aeng
000165166 100__ $$0(orcid)0000-0002-5232-685X$$aCubero, J. L.
000165166 245__ $$aSuccessful Desensitization to Irinotecan After Severe Hypersensitivity Reaction
000165166 260__ $$c2016
000165166 5203_ $$aIrinotecan is an antineoplastic drug that is widely used to treat gastrointestinal malignancies. It prevents DNA from unwinding by inhibition of topoisomerase I. Hypersensitivity reactions (HSRs), which can occur with most drugs, are unpredictable, can affect any organ or system, and range widely in clinical severity from mild pruritus to anaphylaxis. In most cases, the culprit drug is avoided in the future, but for certain patients, the particular drug may be essential for optimal therapy. Under these circumstances, desensitization to the drug in question is a viable option. This approach induces a temporary state of tolerance to the drug responsible for a proven HSR [2]. A 57-year-old man with a personal history of dyslipidemia, high blood pressure, and hyperuricemia and no history of allergy was diagnosed in June 2014 with a low rectal neoplasm 7 cm from the anal margin with synchronous liver metastases (T3N2M1). Short-course radiotherapy was administered, followed by laparoscopic ultralow anterior resection with manual colorectal anastomosis and removal of a surgical specimen through the anus (pass-through) with protective lateral ileostomy...
000165166 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000165166 590__ $$a3.094$$b2016
000165166 591__ $$aIMMUNOLOGY$$b74 / 149 = 0.497$$c2016$$dQ2$$eT2
000165166 591__ $$aALLERGY$$b14 / 26 = 0.538$$c2016$$dQ3$$eT2
000165166 592__ $$a0.645$$b2016
000165166 593__ $$aImmunology and Allergy$$c2016$$dQ3
000165166 593__ $$aImmunology$$c2016$$dQ3
000165166 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000165166 700__ $$aEscudero, P.
000165166 700__ $$aYubero, A.
000165166 700__ $$0(orcid)0000-0003-3045-505X$$aMillan, P.$$uUniversidad de Zaragoza
000165166 700__ $$aSagredo, M. A.
000165166 700__ $$0(orcid)0000-0001-8959-6784$$aColas, C.$$uUniversidad de Zaragoza
000165166 7102_ $$11010$$2770$$aUniversidad de Zaragoza$$bDpto. Pediatría Radiol.Med.Fís$$cÁrea Radiol. y Medicina Física
000165166 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000165166 773__ $$g26, 5 (2016), 314-316$$pJ. investig. allergol. clin. immunol.$$tJournal of Investigational Allergology and Clinical Immunology$$x1018-9068
000165166 8564_ $$s371293$$uhttps://zaguan.unizar.es/record/165166/files/texto_completo.pdf$$yVersión publicada
000165166 8564_ $$s3026023$$uhttps://zaguan.unizar.es/record/165166/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165166 909CO $$ooai:zaguan.unizar.es:165166$$particulos$$pdriver
000165166 951__ $$a2025-12-19-14:42:12
000165166 980__ $$aARTICLE